Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Chemosphere ; 198: 342-350, 2018 May.
Artículo en Inglés | MEDLINE | ID: mdl-29421749

RESUMEN

Polybrominated diphenyl ethers (PBDEs) are a group of brominated flame retardants that are ubiquitously detected in the environment and associated with adverse health outcomes. 6-OH-BDE-47 is a metabolite of the flame retardant, 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47), and there is increasing concern regarding its developmental neurotoxicity and endocrine disrupting properties. In this study, we report that early life exposure in zebrafish (Danio rerio) embryos to 6-OH-BDE-47 (50 and 100 nM) resulted in higher coiling frequency and significantly increased apoptotic cells in the brain. These effects were partially rescued by overexpression of thyroid hormone receptor ß (THRß) mRNA. Moreover, exposure to 100 nM 6-OH-BDE-47 significantly reduced the number of hypothalamic 5-hydroxytryptamine (5-HT, serotonin)-immunoreactive (5-HT-ir) neurons and the mRNA expression of tryptophan hydroxylase 2 (TPH2). These results indicate that 6-OH-BDE-47 affected thyroid hormone regulation through THRß and negatively impacted the nervous system, in turn, affecting coiling behavior. Correlations of these endpoints suggest that coiling frequency could be used as an indicator of neurotoxicity in embryos.


Asunto(s)
Disruptores Endocrinos/toxicidad , Bifenilos Polibrominados/toxicidad , Animales , Apoptosis , Embrión no Mamífero , Disruptores Endocrinos/metabolismo , Retardadores de Llama/metabolismo , Retardadores de Llama/toxicidad , Éteres Difenilos Halogenados/metabolismo , Hipotálamo/metabolismo , Neuronas/efectos de los fármacos , Serotonina/metabolismo , Transducción de Señal , Glándula Tiroides/efectos de los fármacos , Receptores beta de Hormona Tiroidea/metabolismo , Hormonas Tiroideas/metabolismo , Pez Cebra/embriología , Pez Cebra/metabolismo
2.
Cell Chem Biol ; 25(3): 291-300.e3, 2018 03 15.
Artículo en Inglés | MEDLINE | ID: mdl-29337187

RESUMEN

Recently, the palbociclib/letrozole combination therapy was granted accelerated US FDA approval for the treatment of estrogen receptor (ER)-positive breast cancer. Since the underlying metabolic effects of these drugs are yet unknown, we investigated their synergism at the metabolome level in MCF-7 cells. As xenoestrogens interact with the ER, we additionally aimed at deciphering the impact of the phytoestrogen genistein and the estrogenic mycotoxin zearalenone. A global metabolomics approach was applied to unravel metabolite and pathway modifications. The results clearly showed that the combined effects of palbociclib and letrozole on cellular metabolism were far more pronounced than that of each agent alone and potently influenced by xenoestrogens. This behavior was confirmed in proliferation experiments and functional assays. Specifically, amino acids and central carbon metabolites were attenuated, while higher abundances were observed for fatty acids and most nucleic acid-related metabolites. Interestingly, exposure to model xenoestrogens appeared to counteract these effects.


Asunto(s)
Letrozol/farmacología , Metaboloma/efectos de los fármacos , Fitoestrógenos/farmacología , Piperazinas/farmacología , Piridinas/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Carbono/metabolismo , Dieta , Femenino , Genisteína/química , Genisteína/farmacología , Humanos , Letrozol/química , Letrozol/uso terapéutico , Células MCF-7 , Metabolómica , Fitoestrógenos/química , Piperazinas/química , Piperazinas/uso terapéutico , Análisis de Componente Principal , Piridinas/química , Piridinas/uso terapéutico , Receptores de Estrógenos/metabolismo , Zearalenona/química , Zearalenona/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA